Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

A prostate cancer and prostate technology, applied in the field of prostate cancer, can solve the problems that the markers of prostate tumors are worthless and cannot distinguish prostate cancer, etc.

Inactive Publication Date: 2007-08-15
MILLENNIUM PHARMA INC
View PDF57 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these protein markers apparently do not distinguish BPH from prostate cancer (Partin et al., 1993, Cancer Res., 53:744-746)
Unfortunately, markers that cannot distinguish between benign and malignant prostate tumors are of no value

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0313] Example 1: Identification of prostate cancer markers

[0314] Materials and Methods

[0315] RNA preparation

[0316] RNA was prepared from samples derived from prostate tumor specimens, normal prostate specimens, non-prostate tumor specimens, and non-prostate normal specimens. Frozen tissue blocks are sectioned and RNA is isolated from the samples. Total RNA was extracted from frozen tissues using Trizol reagent (Invitrogen, San Diego, CA), followed by a second purification step using Qiagen's RNeasy kit to increase the labeling efficiency of RNA probes (Qiagen, Valencia CA). Only RNA with a 28S / 18S ribosomal RNA ratio of at least 1.0 calculated from ethidium staining of the RNA after agarose gel electrophoresis was used in this study.

[0317] cDNA microarray hybridization

[0318] A cDNA microarray containing 30,732 single gene clones from Research Genetics (Hunstville, AL) was formed on nylon filters. Using a total of 4-6 μg total RNA as template, use 33 Radio...

Embodiment 2

[0346] Example 2: Gene expression analysis by endpoint PCR

[0347] Materials and Methods

[0348] End point PCR analysis

[0349] Briefly, total RNA from different samples was pooled and used as a template for first-strand cDNA generation. Equivalent amounts of each sample are included in the library. The prostate screening group consists of "prostate tumor bank" (3 prostate tumor patient samples), "prostate normal bank" (5 normal prostate epithelial patient samples), "other normal bank" (from normal heart, kidney, small intestine, spleen, WBC , 1 sample each of patient tissue samples of lung, liver, brain, bone marrow, and colon tissue), and "other tumor banks" (4 cervical cancer, 5 colon tumors, 8 different types of lung cancer patient samples, 4 ovarian tumor samples, and 5 prostate tumor samples) patient sample composition (eg, see Table 3).

[0350] Total RNA was prepared from patient samples by a one-step extraction method using TRIZOL reagent according to the instr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to newly discovered nucleic acid molecules and proteins associated with prostate cancer including pre-malignant conditions. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human prostate cancers are provided.

Description

[0001] related application [0002] This application claims priority to US Provisional Application 60 / 601,413, filed August 13, 2004, the entire contents of which are incorporated herein by reference. field of invention [0003] The field of the invention is prostate cancer, including the diagnosis, characterization, management and therapy of prostate cancer. Background of the invention [0004] The increasing number of cancer cases reported both in the United States and indeed around the world are of concern. There are currently only a few effective treatments for specific types of cancer, and there is no guarantee of absolute success. To be most effective, these treatments require not only early detection of malignancy, but also reliable assessment of malignancy severity. [0005] Prostate cancer (PCA) is the most commonly diagnosed cancer in US men and the second leading cause of cancer death in men (Karp et al., 1996, Cancer Res. 56:5547-5556). The acute susceptibilit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C07H21/04
CPCG01N33/573C12N9/90C12Q2600/158G01N2500/00C12Q1/6886C07K14/4748C12Y501/99004G01N33/57434C12Q2600/136C07K16/3069A61P13/08A61P35/00C12Q1/6813
Inventor J·E·莫纳汉S·卡马特卡S·霍尔施B·O·戈巴彻瓦K·格拉特D·福特W·O·恩德格D·L·安德森
Owner MILLENNIUM PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com